

BPV Case ID \_\_\_\_\_

Affix BPV Case ID Barcode Label

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Form Was Completed: \_\_/\_\_/\_\_\_\_\_  
 (MM/DD/YYYY)

**Ovarian Slide Pathology Review**

**1. Slide ID examined by pathologist:**

**2. Parent specimen ID of the sample from which this slide was derived:**

**3. Organ of origin:**

**Select one:**

- Ovary
- Peritoneum
- Fallopian tube
- Indeterminate
- Other (specify)

**Specify other organ of origin:**

**If Other was selected, record other organ of origin:**

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed \_\_\_/\_\_\_/\_\_\_\_\_  
 MM/DD/YYYY

**4. Histologic type:**

**Specify histologic type details where applicable:**

**Select one:**

- Brenner Tumor, malignant type (WHO code: 9000/3)
- Carcinosarcoma (Malignant mullerian mixed tumor) (WHO code: 8950/3)
- Clear cell borderline tumor (WHO code: 8310/1)
- Clear cell carcinoma (WHO code: 8310/3)
- Endometrioid borderline tumor (WHO code: 8380/1)
- Endometrioid carcinoma (WHO code: 8380/3)
- Granulosa cell tumor (WHO code 8620/1)
- Malignant germ cell tumor (WHO code: 9064/3)
- Specify types and %:**
- Mixed epithelial borderline tumor (WHO code: 8323/1)
- Specify types and %:**
- Mixed epithelial carcinoma (WHO code: 8323/3)
- Specify types and %:**
- Mucinous borderline tumor, endocervical (seromucinous) type (WHO code: 8472/1)
- Mucinous borderline tumor, intestinal type (WHO code: 3472/1)
- Mucinous carcinoma (WHO code: 8480/3)
- Mucinous cystadenocarcinoma (WHO code: 8470/3)
- Serous borderline tumor (WHO code: 8441/1)
- Serous carcinoma (WHO code: 8441/3)
- Serous cystadenocarcinoma (WHO code: 8441/3)
- Squamous cell carcinoma
- Transitional cell borderline carcinoma (WHO code: 8120/1)
- Transitional cell carcinoma (WHO code: 8120/3)
- Undifferentiated carcinoma (WHO code: 8020/3)
- Other sex cord-stromal tumor (WHO code: 8590/1)
- Specify types and %:**
- Other
- Specify other histologic type or histologic type details:**

BPV Case ID: _____	Tissue Bank ID: _____
Form Completed By: _____	Date Completed ____/____/_____ MM/DD/YYYY

5. Greatest tumor dimension on slide:	_____ (mm)	
6. Percent of cross-sectional surface area of entire slide composed of tumor focus (includes necrotic tumor):	_____ %	
7. Percent of tumor nuclei by cell count of the entire slide (number of tumor epithelial cell nuclei as compared to all cell nuclei):	_____ %	
8. Percent of cross-sectional surface area of entire slide composed of necrotic tissue:	_____ %	

**Note:** BPV case acceptance criteria require necrosis percentage of <20% of the entire slide AND tumor content of ≥50% tumor nuclei.

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed \_\_\_\_/\_\_\_\_/\_\_\_\_\_  
 MM/DD/YYYY

<b>9. Histologic profile quantitative assessment:</b>	Percent viable tumor by surface area (not including stroma)	%
	Percent necrotic tumor by surface area	%
	Percent tumor stroma by surface area	%
	Percent non-cellular component by surface area (i.e., mucin, hemorrhage, blood clot, etc.)  <b>If present, describe non-cellular component:</b>	%
	Histologic profile total % ( <b>should equal 100%</b> ):	%

PR-0009-F2

VER. 03.02

Effective Date: 07/16/2014

Page 5 of 8

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed \_\_\_\_/\_\_\_\_/\_\_\_\_\_  
 MM/DD/YYYY

**10. What histologic grading system was applied?**

**Select One:**

- WHO grading system
- Record WHO histologic grade:**
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- G4: Undifferentiated
- GX: Cannot be assessed

**OR**

- Two-tier grading system
- Record two-tier histologic grade:**
- Low grade
- High grade

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed \_\_\_\_/\_\_\_\_/\_\_\_\_\_  
 MM/DD/YYYY

**Tumor Staging per AJCC 7th Edition**

**11. pT: Pathologic spread primary tumor (AJCC 7th edition):**

**Select One:**

- pTX
- pT0
- pT1
  - pT1a
  - pT1b
  - pT1c
- pT2
  - pT2a
  - pT2b
  - pT2c
- pT3
  - pT3a
  - pT3b
  - pT3c

**12. pN: Pathologic spread lymph nodes (AJCC 7th edition):**

**Select One:**

- pNX
- pN0
- pN1

**13. M: Distant metastases (AJCC 7th edition):**

**Select One:**

- cM0
- cM1
- pM1

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed \_\_\_\_/\_\_\_\_/\_\_\_\_\_  
 MM/DD/YYYY

14. Pathologic tumor stage grouping (FIGO):

Select One:

- Stage 1
- Stage 1A
- Stage 1B
- Stage 1C
- Stage 2
- Stage 2A
- Stage 2B
- Stage 2C
- Stage 3
- Stage 3A
- Stage 3B
- Stage 3C
- Stage 4
- Stage unknown

15. Did pathology review of the hematoxylin and eosin slide derived from quality control formalin-fixed paraffin-embedded tumor tissue confirm the histological type to be eligible for BPV study?

Select One:

- Yes
- No

16. This slide meets the microscopic analysis criteria of the BPV project of necrosis percentage of <20% AND tumor content of ≥50% tumor nuclei:

Select One:

- Yes
- No

If No is selected, specify what findings do not meet the microscopic analysis criteria of the BPV project:

17. Pathology review comments:

BPV Case ID: _____	Tissue Bank ID: _____
Form Completed By: _____	Date Completed ____/____/_____ MM/DD/YYYY

Concordance With Diagnostic Pathology Report	
18. This slide is consistent with the findings of the diagnostic pathology report for this case:	Select One: <input type="radio"/> Yes <input type="radio"/> No If No is selected, specify what findings are not consistent with the diagnostic pathology report:
19. Name of local biospecimen source site reviewing pathologist:	
20. Date of slide review by the pathologist:	
21. Data entry in the local pathology review form was performed by:	